Loading the security overview…
Where the tokens are
Peers
6 of 14 have tokenized versionsFirst the companies classified under the same themes, most themes in common first; then the ones investors most often look at alongside GILD. A peer with a tokenized version links to its own page, where every issuer that wraps it is listed.
| Company | Shared themes | Market cap | P/E | P/S | EV/EBITDA | ROE | F-Score | Altman zone |
|---|---|---|---|---|---|---|---|---|
 GILDThis companyGilead Sciences Inc | — | $182.89B | — | 6.0 | 63.8 | −27.4% | 8/9 | safe |
 MRKTokenizedMerck & Co., Inc. | Infectious Disease & Vaccines | $354.8B | 111.8 | 5.3 | 29.3 | 7.6% | 5/9 | safe |
 PFETokenizedPfizer Inc. | Infectious Disease & Vaccines | $160.27B | 37.0 | 2.5 | 9.4 | 5.1% | 6/9 | safe |
 GSKTokenizedGSK plc American Depositary Shares (Each representing two Ordinary Shares) | Infectious Disease & Vaccines | $101.06B | — | — | — | — | 8/9 | — |
 MRNATokenizedModerna, Inc. Common Stock | Infectious Disease & Vaccines | $75.43B | — | 33.9 | -24.1 | −46.6% | 2/9 | safe |
 BNTXTokenizedBioNTech SE American Depositary Share | Infectious Disease & Vaccines | $26.08B | — | — | — | — | — | — |
 SMMTTokenizedSummit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.31B | — | — | -14.7 | −135.9% | 1/9 | safe |
 PCVXVaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $8.34B | — | — | -7.2 | −38.6% | 1/9 | safe |
 ACLXArcellx, Inc. Common Stock | Cell & Gene Therapy for Cancer | $6.73B | — | 302.1 | -27.0 | −56.9% | 1/9 | safe |
 IOVAIovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for Cancer | $6.45B | — | 19.8 | -24.4 | −39.3% | 3/9 | safe |
 LEGNLegend Biotech Corporation American Depositary Shares | Cell & Gene Therapy for Cancer | $4.26B | — | — | — | — | 3/9 | — |
 BCRXBioCryst Pharmaceuticals Inc | Infectious Disease & Vaccines | $2.07B | — | 2.2 | -8.8 | 84.7% | 7/9 | distress |
 VIRVir Biotechnology, Inc. Common Stock | Infectious Disease & Vaccines | $1.91B | — | 6.3 | -6.1 | −25.6% | 3/9 | safe |
 GLPGGalapagos NV | Cell & Gene Therapy for Cancer | $1.87B | — | — | — | — | — | — |
 NVAXNovavax Inc | Infectious Disease & Vaccines | $1.75B | — | 4.2 | -15.7 | 129.9% | 5/9 | distress |
Figures describe Gilead Sciences shares, not any token. From theme classifications, Massive's related companies and the latest ratios and scores. Ratios are trailing, each as of its own latest filing. Peers are for comparison, not a list of alternatives to buy.